What if a tiny peptide could ask the pituitary gland to release growth hormone? Meet ipamorelin: five amino acids designed to trigger that signal. In 1998, Kirsten Raun and colleagues at Novo Nordisk in Denmark reported its discovery. Researchers have studied it for almost three decades. Ipamorelin activates the ghrelin receptor, part of the body's growth-hormone signaling system. CJC-1295 and tesamorelin act through a different receptor, the growth-hormone-releasing hormone receptor. In the original pig experiments, ipamorelin stimulated growth hormone without the same rise in cortisol seen with some older secretagogues. That selectivity attracted interest. A 1999 study in healthy men then showed a brief growth-hormone response after intravenous ipamorelin. It measured hormone release, leaving long-term health benefits unanswered. Researchers also explored ghrelin signaling in the gut. A randomized trial enrolled 117 bowel-surgery patients. The ipamorelin group tolerated a meal sooner numerically, but the difference was not statistically significant. So where do the muscle, sleep and anti-aging claims fit? A hormone response alone cannot establish those benefits. Different receptor pathways also cannot tell us how much benefit a particular peptide combination provides. As of November 2026, ipamorelin has no FDA-approved medicine. FDA has raised concerns about immune reactions, peptide impurities and limited safety evidence. Its story connects molecular design, human hormone measurements and an unfinished clinical question: which effects translate into meaningful benefits? World Peptide Foundation. Peptides in 2. Every experience matters.